United Therap Drug Patent Portfolio
United Therap owns 4 orange book drugs protected by 33 US patents Given below is the list of United Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease | 03 Feb, 2042 | Active |
| US10421729 | Microcrystalline diketopiperazine compositions and methods | 01 Apr, 2035 | Active |
| US8747897 | Osmotic drug delivery system | 11 Aug, 2031 | Active |
| US8349892 | Solid formulations of prostacyclin analogs | 22 Jan, 2031 | Active |
| US10772883 | Diketopiperazine microparticles with defined specific surface areas | 11 Jun, 2030 | Active |
| US8410169 | Compounds and methods for delivery of prostacyclin analogs | 13 Feb, 2030 | Active |
| US7999007 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 29 Mar, 2029 | Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® | 15 Dec, 2028 | Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US8653137 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 05 Sep, 2028 | Active |
| US8658694 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 05 Sep, 2028 | Active |
| US9358240 | Treprostinil administration by inhalation | 05 May, 2028 | Active |
| US9339507 | Treprostinil administration by inhalation | 10 Mar, 2028 | Active |
| US10376525 | Treprostinil administration by inhalation | 14 May, 2027 | Active |
| US10716793 | Treprostinil administration by inhalation | 14 May, 2027 | Active |
| US7417070 | Compounds and methods for delivery of prostacyclin analogs | 30 Jul, 2026 | Active |
| US9393203 | Osmotic drug delivery system | 27 Apr, 2026 | Active |
| US10130685 | Diketopiperazine salts for drug delivery and related methods | 23 Aug, 2025 | Active |
| US10076505 | Inhalation formulations of Treprostinil | 16 Dec, 2024 | Expired |
| US10695308 | Inhalation formulations of treprostinil | 16 Dec, 2024 | Expired |
| US9713599 | Parenteral formulations of treprostinil | 16 Dec, 2024 | Expired |
| US7544713 | Compounds and methods for delivery of prostacyclin analogs | 14 Jul, 2024 | Expired |
| US8252839 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9050311 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9278901 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9422223 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9199908 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US6521212 | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation | 13 Nov, 2018 | Expired |
| US6756033 | Method for delivering benzindene prostaglandins by inhalation | 13 Nov, 2018 | Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives | 24 Oct, 2017 | Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins | 16 Oct, 2014 | Expired |
Latest Legal Activities on United Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of United Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Mar, 2024 | US10772883 |
|
Email Notification
Critical
| 09 Mar, 2024 | US11826327 |
|
Email Notification
Critical
| 09 Mar, 2024 | US11826327 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 08 Mar, 2024 | US11826327 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 08 Mar, 2024 | US11826327 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 08 Mar, 2024 | US11826327 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 08 Mar, 2024 | US11826327 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 07 Mar, 2024 | US11826327 |
| Adjustment of PTA Calculation by PTO | 07 Mar, 2024 | US11826327 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 07 Mar, 2024 | US11826327 |
| Adjustment of PTA Calculation by PTO | 07 Mar, 2024 | US11826327 |
| Pet Dec Routed to Certificate of Corrections Branch | 07 Mar, 2024 | US11826327 |
| Pet Dec Routed to Certificate of Corrections Branch | 07 Mar, 2024 | US11826327 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Feb, 2024 | US8252839 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Feb, 2024 | US9422223 |
United Therap's Drug Patent Litigations
United Therap's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 02, 2015, against patent number US8497393. The petitioner SteadyMed Ltd., challenged the validity of this patent, with United Therapeutics Corporation as the respondent. Click below to track the latest information on how companies are challenging United Therap's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10716793 | January, 2021 |
Final Written Decision - Appealed
(02 Feb, 2023)
| United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 |
FWD Entered
(08 Oct, 2021)
| United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US9593066 | March, 2020 |
Terminated-Denied
(13 Oct, 2020)
| United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9339507 | June, 2017 |
Terminated-Settled
(27 Aug, 2018)
| United Therapeutics Corp. | Watson Laboratories, Inc. |
| US9358240 | June, 2017 |
Terminated-Settled
(27 Aug, 2018)
| United Therapeutics Corp. | Watson Laboratories, Inc. |
| US8497393 | October, 2015 |
FWD Entered
(31 Mar, 2017)
| United Therapeutics Corporation | SteadyMed Ltd. |
United Therap Drug Patents' Oppositions Filed in EPO
United Therap drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 08, 2012, by Sandoz Ag. This opposition was filed on patent number EP07755989A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13188882A | Dec, 2019 | Generics [UK] Ltd | Revoked |
| EP13188882A | Nov, 2019 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP04776104A | Oct, 2017 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP08829225A | Oct, 2016 | Generics (U.K.) Limited | Revoked |
| EP08829225A | Sep, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP07755989A | Aug, 2012 | Sandoz AG | Revoked |
United Therap's Family Patents
United Therap drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 39.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
United Therap Drug List
Given below is the complete list of United Therap's drugs and the patents protecting them.
1. Orenitram
Orenitram is protected by 16 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8747897 | Osmotic drug delivery system |
11 Aug, 2031
(6 years from now)
| Active |
| US8349892 | Solid formulations of prostacyclin analogs |
22 Jan, 2031
(6 years from now)
| Active |
| US8410169 | Compounds and methods for delivery of prostacyclin analogs |
13 Feb, 2030
(5 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US7417070 | Compounds and methods for delivery of prostacyclin analogs |
30 Jul, 2026
(1 year, 7 months from now)
| Active |
| US9393203 | Osmotic drug delivery system |
27 Apr, 2026
(1 year, 4 months from now)
| Active |
| US7544713 | Compounds and methods for delivery of prostacyclin analogs |
14 Jul, 2024
(5 months ago)
| Expired |
| US8252839 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(6 months ago)
| Expired |
| US9050311 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(6 months ago)
| Expired |
| US9278901 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(6 months ago)
| Expired |
| US9422223 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(6 months ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(7 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
16 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orenitram's drug page
2. Remodulin
Remodulin is protected by 13 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7999007 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
29 Mar, 2029
(4 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US8653137 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
05 Sep, 2028
(3 years from now)
| Active |
| US8658694 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
05 Sep, 2028
(3 years from now)
| Active |
| US10076505 | Inhalation formulations of Treprostinil |
16 Dec, 2024
(6 days ago)
| Expired |
| US10695308 | Inhalation formulations of treprostinil |
16 Dec, 2024
(6 days ago)
| Expired |
| US9713599 | Parenteral formulations of treprostinil |
16 Dec, 2024
(6 days ago)
| Expired |
| US9199908 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(6 months ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(7 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
06 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Remodulin's drug page
3. Tyvaso
Tyvaso is protected by 13 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease |
03 Feb, 2042
(17 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9358240 | Treprostinil administration by inhalation |
05 May, 2028
(3 years from now)
| Active |
| US9339507 | Treprostinil administration by inhalation |
10 Mar, 2028
(3 years from now)
| Active |
| US10376525 | Treprostinil administration by inhalation |
14 May, 2027
(2 years from now)
| Active |
| US10716793 | Treprostinil administration by inhalation |
14 May, 2027
(2 years from now)
| Active |
| US6521212 | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
13 Nov, 2018
(6 years ago)
| Expired |
| US6756033 | Method for delivering benzindene prostaglandins by inhalation |
13 Nov, 2018
(6 years ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(7 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
16 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyvaso's drug page
4. Tyvaso Dpi
Tyvaso Dpi is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease |
03 Feb, 2042
(17 years from now)
| Active |
| US10421729 | Microcrystalline diketopiperazine compositions and methods |
01 Apr, 2035
(10 years from now)
| Active |
| US10772883 | Diketopiperazine microparticles with defined specific surface areas |
11 Jun, 2030
(5 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(3 years from now)
| Active |
| US10716793 | Treprostinil administration by inhalation |
14 May, 2027
(2 years from now)
| Active |
| US10130685 | Diketopiperazine salts for drug delivery and related methods |
23 Aug, 2025
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyvaso Dpi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List